logo
  Join        Login             Stock Quote

Medgenics (MDGN): Patent Granted for Tissue-Based Platform Technology

 November 21, 2012 10:35 AM


(By Balachander) Medgenics Inc. (NYSEAMEX: MDGN), a protein-therapeutics medical technology company, said it has received a patent for core technology used in sustained delivery of Erythropoietin.

The U.S. Patent and Trademark Office (USPTO) granted method patents and allowance of key claims for Medgenics' EPODURE Biopump system for delivery of erythropoietin (EPO) and clotting Factor VIII proteins.

Medgenics is developing Biopump, a tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia.

[Related -Medgenics (MDGN) Starts Phase 2A Anemia Study On Kidney Failure Patients In Israel]

The global protein therapy market which is forecast to reach $132 billion in 2013.

Medgenics said its approach to protein therapy has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.

In total, Medgenics' global portfolio now includes 36 patents issued, with 81 more pending.

Medgenics noted that similar claims covering EPODURE and HEMODURE have also been recently allowed in Japan, China, Korea and Australia.

On Wednesday, the stock jumped 8.45 percent to trade at $7.70. Over the past year, shares have been trading between $2.08 and $16.43.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThe Eurozone: On The Road To Recovery With A Lingering Risk

Back in September the idea that the Eurozone's economy could potentially undergo a recovery (see post) was read on...

article imageAversion to the Mean

Stocks’ gangbusters February doesn’t mean March must be a read on...

article imageNasdaq Back To 2000 Peak But What About Investors' Portfolios?

I hope Wall Street and CNBC don’t insult the intelligence of investors who were fully invested at the read on...

article imageStocks Break Out Again But May Be Running On Fumes

Despite low trading volume, a strong dollar, mixed economic and earnings reports, paralyzing weather read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.